Even if the expressions of GABRA3, CECR7, TRIM16L, and IL7R are obviously changed in HCC in the United States and are associated with TMB and immune infiltration, this does not mean that this risk prediction model can provide a basis for immunotherapy in actual clinical practice. The gene discussed is GABRA3; the disease is hepatocellular carcinoma.